Compare PLUS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUS | TRVI |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1996 | 2019 |
| Metric | PLUS | TRVI |
|---|---|---|
| Price | $95.07 | $14.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $28.18 |
| AVG Volume (30 Days) | 219.8K | ★ 1.8M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | 24.20 | ★ 31.91 |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $2,442,549,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $34.71 | ★ N/A |
| Revenue Growth | ★ 18.07 | N/A |
| 52 Week Low | $73.09 | $9.82 |
| 52 Week High | $98.21 | $20.22 |
| Indicator | PLUS | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 57.32 |
| Support Level | $85.87 | $13.08 |
| Resistance Level | $98.03 | $14.75 |
| Average True Range (ATR) | 4.31 | 0.81 |
| MACD | -0.13 | 0.29 |
| Stochastic Oscillator | 84.64 | 74.09 |
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.